ORL-1 Inhibitors
2 drugsAbout ORL-1
The opioid receptor-like 1 receptor (ORL-1) modulates pain pathways, making it a protein target of interest for pain management.
ORL-1 is a viable therapeutic target for pain, evidenced by two approved drugs, BUPRENORPHINE and BUTRANS. Currently, there is no genetic evidence data available linking ORL-1 to specific diseases.
ORL-1 is targeted by two FDA-approved small molecule drugs, BUPRENORPHINE and BUTRANS, both indicated for pain relief. WATSON LABS TEVA and PURDUE PHARMA LP are the companies marketing these drugs.
Top ORL-1 Drugs
Only two companies, WATSON LABS TEVA and PURDUE PHARMA LP, have approved drugs targeting ORL-1.
Low market concentration suggests an opportunity for new entrants to gain market share.
ORL-1 Drug Modality Landscape
Modalities
Routes of Administration
ORL-1 is druggable by small molecules, though no oral formulations are currently approved.
Explore opportunities for novel modalities like antibodies or peptides to differentiate from existing treatments.
ORL-1 Clinical Trials 208 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on ORL-1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 42 | 35 | 3 | 4 | 92% |
| Phase 2 | 47 | 32 | 7 | 8 | 82% |
| Phase 3 | 45 | 30 | 9 | 5 | 77% |
| Phase 4 | 74 | 39 | 14 | 20 | 74% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
ORL-1 Drug Approval Timeline (2010 - 2018)
The first drug targeting ORL-1 was approved in 2010, and the most recent in 2018.
Slow approval rate indicates a potentially challenging development path or limited investment in this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 115 (27 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on ORL-1. A trial counts if an approved drug acting on ORL-1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.